

1 Title: Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

2

3 Authors: Julie Boucau¹, Kara W. Chew², Manish Choudhary³, Rinki Deo³, James Regan³,
4 James P. Flynn³, Charles R. Crain³, Michael D. Hughes⁴, Justin Ritz⁴, Carlee Moser⁴, Joan A.
5 Dragavon⁵, Arzhang C. Javan⁶, Ajay Nirula⁷, Paul Klekotka⁷, Alexander L. Greninger⁵, Robert
6 W. Coombs⁵, William A Fischer II⁸, Eric S. Daar⁹, David A. Wohl⁸, Joseph J. Eron⁸, Judith S.
7 Currier², Davey M Smith¹⁰, Jonathan Z. Li³ *, Amy K. Barczak^{1,11} * for the ACTIV-2/A5401 Study
8 Team.

9

- 10 1. The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA
- 11 2. University of California, Los Angeles, Los Angeles, CA
- 12 3. Brigham and Women's Hospital, Harvard Medical School, Boston, MA
- 13 4. Harvard T.H. Chan School of Public Health, Boston, MA
- 14 5. University of Washington, Seattle, WA
- 15 6. National Institutes of Health, Bethesda, MD
- 16 7. Lilly Research Laboratories, San Diego, CA
- 17 8. University of North Carolina, Chapel Hill, N
- 18 9. Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA
- 19 10. University of California, San Diego, San Diego, CA
- 20 11. Massachusetts General Hospital, Harvard Medical School, Boston MA

21 * Co-communicating

22

23 **Abstract**

24 Monoclonal antibodies (mAbs) are the treatment of choice for high-risk ambulatory persons with
25 mild to moderate COVID-19. We studied viral culture dynamics post-treatment in a subset of
26 participants receiving the mAb bamlanivimab in the ACTIV-2 trial. Viral load by qPCR and viral
27 culture were performed from anterior nasal swabs collected on study days 0 (day of treatment),
28 1, 2, 3, and 7. Treatment with mAb resulted in rapid clearance of culturable virus in participants
29 without treatment-emergent resistance. One day after treatment, 0 of 28 (0%) participants
30 receiving mAb and 16 of 39 (41%) receiving placebo still had culturable virus (p <0.0001); nasal

31 viral loads were only modestly lower in the mAb-treated group at days 2 and 3. Recrudescence
32 of culturable virus was detected in three participants with emerging mAb resistance and viral
33 load rebound. The rapid reduction in shedding of viable SARS-CoV-2 after mAb treatment
34 highlights the potential role of mAbs in preventing disease transmission.

35

36

37 **Main**

38 As the COVID-19 pandemic progresses, interventions have been developed to prevent
39 transmission and progression to severe disease in infected persons. Monoclonal antibodies
40 (mAbs) are currently first-line therapy for the outpatient management of high-risk individuals with
41 mild to moderate COVID-19 (<https://www.covid19treatmentguidelines.nih.gov>). These mAbs
42 have been shown to accelerate the decay of SARS-CoV-2 levels in the upper respiratory tract
43 ^{1,2}, but their effects on duration of shedding viable virus is unknown. While viral RNA is
44 commonly used to assess viral burden, culture of viable virus from infected persons could be a
45 more sensitive indicator of antiviral activity and potential for viral transmission. We hypothesized
46 that reduction in shedding of viable virus might occur more rapidly than reduction in anterior
47 nasal SARS CoV-2 RNA levels following mAb treatment. A full understanding of the potential
48 benefits of mAbs and other treatments should help determine their optimal use for preventing
49 and treating SARS-CoV-2 infection.

50 Bamlanivimab is a neutralizing mAb that binds to the spike protein of SARS-CoV-2,
51 preventing uptake into host cells ³. It currently has emergency use authorization for use in
52 conjunction with etesevimab for treatment of non-hospitalized, high-risk individuals with SARS-
53 CoV-2 infection and for post-exposure prophylaxis. We performed viral culture analysis of
54 participants enrolled in the ACTIV-2 randomized placebo-controlled trial of bamvalinimab
55 monotherapy for non-hospitalized adults with mild to moderate COVID-19 ⁴. In that study,

56 bamlanivimab treatment reduced respiratory tract (nasopharyngeal) viral load by 3 days post-
57 treatment.

58 To compare shedding of viable virus and change in anterior nasal sample SARS CoV-2
59 RNA over time after treatment with mAb, we cultured virus from anterior nasal swabs collected
60 from participants enrolled in the ACTIV-2 study⁴ who had baseline (pre-treatment, day 0) viral
61 load of $\geq 6 \log_{10}$ SARS-CoV-2 RNA copies/mL and available swab samples from study days 0,
62 1, 2, 3 and 7. Participants with evidence of bamlanivimab resistance mutations at baseline or
63 during follow-up based on our previous viral sequencing work⁵ were initially excluded. Of the
64 317 participants in the ACTIV-2 study, 69 met inclusion criteria for the primary analysis in this
65 study: 310 had available day 0 AN swabs, 94 had baseline viral load $\geq 6 \log_{10}$ SARS-CoV-2
66 RNA copies/mL, and 73 had swabs available at days 0, 1, 2, 3, 7. Four participants were
67 excluded from the primary analysis due to emergent resistance identified in our previous work⁵.
68 Of the 69 participants meeting inclusion criteria, 39 participants fell into the placebo arm and 30
69 participants fell into the bamlanivimab arm (20 received the 7000mg dose and 10 received the
70 700mg dose). Baseline participant characteristics, including age, race, comorbidities, days of
71 symptoms before enrollment, and serostatus, were similar between groups (Supp. Table 1).
72 Baseline anterior nasal viral load was also similar between groups (Fig. 1A). Baseline viral
73 culturability, as determined by cytopathic effect (CPE), was also similar between groups, with
74 39/39 (100%) participants in the placebo arm and 28/30 (93%) participants in the mAb arm with
75 culture positive baseline sample (Fig. 1A). For samples with a sufficient number of positive wells
76 to calculate semiquantitative viral culture titer (tissue culture infectious dose 50 [TCID₅₀]) (34
77 placebo and 23 mAb samples), the relationship between SARS CoV-2 RNA and
78 semiquantitative viral TCID₅₀ was also similar between groups at the time of enrollment (Fig.
79 1B).

80 Participants received either placebo or bamlanivimab on day 0. Anterior nasal sample
81 SARS CoV-2 RNA was assessed prior to treatment (day 0) and at study days 1, 2, 3, and 7
82 post-treatment. Shedding of culturable virus was assessed prior to treatment (day 0) and at
83 study days 1 and 2 post-treatment. For participants positive at either day 1 or day 2, culturability
84 was further assessed at study days 3 and 7. While study day 1 nasal swab viral loads were
85 similar between arms (Fig. 1C), significant difference in culture positivity was observed by day 1.
86 In the placebo arm, culture positivity rate was 16/39 (41%) in the placebo arm vs 0/28 (0%) in
87 the bamlanivimab arm ($P < 0.0001$, Fig. 1D). In the placebo arm on day 1, the lowest viral load
88 associated with a positive culture was $5.5 \log_{10}$ RNA copies/mL, and 16/25 (64%) of placebo
89 arm samples with a viral load $\geq 5.5 \log_{10}$ RNA copies/mL were also found to be culture positive.
90 In contrast, all 18 samples from the bamlanivimab arm with viral loads $\geq 5.5 \log_{10}$ RNA
91 copies/mL were culture negative. By day 2 post-treatment, 7 of 39 (18%) participants in the
92 placebo arm were still culture positive; all participants in the bamlanivimab arm remained culture
93 negative. 15 participants in the placebo arm and 0 participants in the bamlanivimab arm were
94 culture positive at study day 1 and/or 2 and underwent additional testing on samples from days
95 3 and 7. Day 3, five of 15 tested placebo participants remained culture positive, and on study
96 day 7, one of 15 tested placebo participants remained culture positive.

97 Viral resistance to bamlanivimab monotherapy has been described both *in vitro* and
98 clinically, with resistance attributed to defined mutations in the SARS-CoV-2 spike protein⁵⁻⁷.
99 We previously identified participants from ACTIV-2 with emergent bamlanivimab resistance
100 mutations⁵ and these individuals were excluded from our primary analysis. We hypothesized
101 that early viral culture clearance observed following bamlanivimab treatment was due to mAb
102 binding and neutralization of virions, and that mAb resistance emergence would lead to
103 renewed shedding of culturable virus. To test this hypothesis, we evaluated four participants
104 with treatment-emergent bamlanivimab resistance mutations identified in our previous work⁵;

105 virus from three participants had emergent E484K mutation and one had emergent E484Q
106 mutation. All four participants had positive viral cultures at day 0; similar to other participants in
107 the bamlanivimab treatment arm of this substudy, all four individuals converted their cultures to
108 negative on day 1 (Fig. 2A). However, the emergence of the E484K mutation following
109 bamlanivimab treatment in the three participants was associated with rebound in viral loads and
110 return of positive viral cultures with rising TCID₅₀ levels (Fig. 2B-D). The participant with
111 emergent E484Q mutation in their infecting virus had only modest increases in viral load and no
112 re-emergence of positive viral cultures (Fig. 2E).

113 Our results demonstrate that bamlanivimab treatment drives a rapid reduction in anterior
114 nasal shedding of culturable virus that precedes a detectable reduction in viral load. Our
115 findings suggest that viral culture assays could provide a means for the rapid evaluation of new
116 mAb therapies in neutralizing infectious virus, which could accelerate the evaluation of mAbs in
117 early phase clinical trials. While the effectiveness of a therapy is typically evaluated based on
118 benefit to the infected individual, our results suggest that mAb treatment for COVID-19 may
119 have an additional public health benefit, potentially reducing the period of infectiousness and
120 consequently reducing the risk of secondary transmission. Whether this reduction in shedding of
121 viable virus is unique to treatment with mAbs or would be similarly observed with other
122 treatments, such as antiviral drugs with different mechanisms of action, is incompletely known.
123 A recent study demonstrating reduction in culturable SARS-CoV-2 by study day 3 in participants
124 treated with molnupiravir relative to placebo suggests that this benefit is not specific to mAb
125 treatment, but may hold across a range of COVID-19 therapies⁸. The time frame to negative
126 culture warrants further evaluation across treatment modalities.

127 In this substudy, we focused on the subset of individuals most likely to have positive
128 baseline cultures, namely those with baseline viral load of $\geq 6 \log_{10}$ SARS-CoV-2 RNA
129 copies/mL. Based on the association we have previously observed between SARS-CoV-2

130 anterior nasal RNA level and likelihood of shedding culturable virus⁹⁻¹¹, individuals with lower
131 baseline viral loads would be more likely to be culture negative at presentation. The precise
132 relationship between baseline anterior nasal swab culture positivity, RNA level, and viral
133 transmissibility remains to be determined; whether with further optimization, virus could be
134 reliably cultured from samples with lower viral loads remains to be determined. However, the
135 potential benefits of rapid culture conversion and reduced transmission might be greatest for
136 individuals with high viral loads and those presenting early in the course of illness, who are most
137 likely to be culture positive¹².

138 Additionally, our results underscore the importance of using mAbs in combinations to
139 avoid the emergence of and selection for viral resistance. The re-emergence of culturable virus
140 in a subset of ACTIV-2 participants with treatment-emergent drug resistance suggests that the
141 development of resistance mutations may lead to a return of infectiousness and the risk of
142 transmission of mAb-resistant strains. These results suggest that time to initial culture
143 conversion and sustained culture conversion provide complementary information, and merit
144 consideration of inclusion as outcome metrics in future studies of SARS-CoV-2 therapies.
145 Understanding the virologic consequences of therapeutic interventions for SARS-CoV-2
146 infection is critical for informing both the development of optimized treatment regimens and
147 public health recommendations after treatment.

148

149

150 **Figure Legends**

151 **Supplementary Table 1.** Baseline characteristics of participants in the placebo and
152 bamlanivimab (700mg and 7000mg) arms.

153

154 **Figure 1. Bamlanivimab treatment results in rapid SARS-CoV-2 culture conversion.** (A)

155 Pre-treatment culture positivity and viral load (B) Pre-treatment TCID₅₀ values vs. viral load;

156 TCID₅₀ could only be calculated for participants with ≥ 3 wells showing CPE. Spearman
157 correlations: placebo $r = 0.8482$, $p\text{-value} < 0.0001$; Bam mAb $r = .6365$, $p\text{-value} = 0.0011$. (C)
158 Decay in qPCR-determined viral load over time post-treatment (D) Culture positivity and viral
159 load over time post-treatment. Cx, culture. Bam mAb, bamlanivimab monoclonal antibody.

160

161 **Figure 2. Emergence of bamlanivimab resistance mutations correlates with recrudescent**
162 **shedding of culturable virus.** (A) Viral load and culture positivity at baseline and day 1 post-
163 treatment for four study participants with recrudescent shedding of culturable virus. Cx, culture
164 (B-E) Viral load and TCID₅₀ for four study participants whose infecting virus developed E484
165 mutations of the spike protein following bamlanivimab monotherapy.

166

167

168 **On-line Methods**

169

170 ***Study participants***

171 ACTIV-2 is a multi-center randomized, blinded placebo-controlled phase 2/3 platform trial in
172 non-hospitalized adults⁴. ACTIV-2 participants were enrolled at 39 sites in the U.S. between
173 August 19 and November 17 2020. ACTIV-2 focused on the safety and efficacy of monoclonal
174 antibody (mAb) bamlanivimab infusion in non-hospitalized participants with positive SARS-CoV-
175 2 antigen or nucleic acid test within 7 days and less than 10 days of COVID-19 symptoms.
176 There were two cohorts with different dosages of bamlanivimab (700 and 7000mg) in ACTIV-2,
177 however due to low numbers, the two intervention groups were analyzed together. The study
178 protocol was approved by the Mass General Brigham IRB as a secondary use protocol. Serial
179 anterior nasal (AN) samples were self-collected by participants daily between enrollment (day 0)
180 and day 14.

181

182 ***Participant selection- substudy***

183 Inclusion criteria for this substudy included baseline (pre-treatment, day 0) AN viral load of ≥ 6
184 \log_{10} SARS-CoV-2 RNA copies/mL, available AN swab samples from study days 0, 1, 2, 3 and
185 7. Participants otherwise meeting criteria for inclusion but with evidence of bamlanivimab
186 resistance mutations at baseline or during follow-up based on our previous viral sequencing
187 work ⁵ were excluded from the primary analysis and were analyzed as a separate emergent
188 resistance subset.

189

190 ***Viral culture***

191 Viral culture experiments were performed as previously reported in the BSL3 laboratory of the
192 Ragon Institute of MGH, MIT, and Harvard ⁹⁻¹¹. Briefly, Vero-E6 cells were maintained in
193 Dulbecco's Modified Eagle Medium (DMEM) supplemented with HEPES,
194 Penicillin/Streptomycin, Glutamine, and 10% Fetal Bovine serum (FBS), detached using
195 Trypsin-EDTA and seeded at 75,000 cells per well in 24-well plates or 20,000 cells per well in
196 96-well plates 16-20 hours before infection. AN specimens were thawed on ice, filtered through
197 a Spin-X 0.45 or 0.65 μ m centrifugal filters at 10,000 x g for 5min and diluted them 1:10 in
198 DMEM supplemented with HEPES, Penicillin/Streptomycin and Glutamine. 100 μ L of the diluted
199 solution was used to inoculate triplicate wells in a 24-well plate for large scale culture
200 experiments. After 1 hour of incubation at 37°C and 5% CO₂, the viral inoculum was removed
201 and 1mL of DMEM supplemented with HEPES, Penicillin/Streptomycin and Glutamine and 2%
202 FBS (D2+) was added to each well. For the TCID₅₀ experiments, 25 μ L of the undiluted filtrate
203 was added to four wells of a 96-well plate and serially diluted (1:5) in D2+ media containing
204 5 μ g/mL of polybrene. The 96-well plates were then spininfected for 1 hour at 2000 x g at 37°C.
205 The SARS-CoV-2 isolate USA-WA1/2020 strain and DMEM supplemented with HEPES,
206 Penicillin/Streptomycin and Glutamine were used as positive and negative controls,

207 respectively. We observed viral culture plates at 3- and 7-days post-infection with a light
208 microscope and documented wells showing cytopathic effect (CPE). TCID₅₀ titers were
209 calculated using the Spearman-Kärber method. In previous work, we had found that our assay
210 was highly likely to grow virus for samples with RNA levels $\geq 6 \log_{10}$ RNA copies/mL⁹⁻¹¹.

211

212 ***Culture positivity***

213 Specimens were defined as culture positive if at least 1 out of 3 wells showed CPE in the 24-
214 well culture experiments or 1 out of 24 wells showed CPE in the TCID₅₀ experiments. Because
215 of the calculation method for TCID₅₀ titers, TCID₅₀ titers could only be calculated for samples
216 with ≥ 3 wells showing CPE. Specimens with no observable CPE in either 24 well or TCID₅₀
217 experiments were defined as culture negative. The USA WA-1/2020 strain was used as a
218 positive control in all experiments.

219

220 ***Statistics/Calculations***

221 Statistical analyses were performed using PRISM software v9.2.0. Comparison of viral loads
222 between the placebo and bamlanivimab treatment arms at the different time points was
223 performed using the non-parametric two-tailed Mann-Whitney test. Comparison of proportion of
224 culture conversion between the placebo and bamlanivimab treatment arms at the different time
225 points was performed using two-sided Fisher's exact test on a 2x2 contingency table.

226

227 ***Data availability***

228 The authors confirm that all data underlying the findings are fully available. Due to ethical
229 restrictions, study data are available upon request from sdac.data@sdac.harvard.edu with the
230 written agreement of the AIDS Clinical Trials Group and the manufacturer of the investigational
231 product.

232

233 **Funding**

234 This work was supported by the National Institute of Allergy and Infectious Diseases of the
235 National Institutes of Health under Award Number 3UM1AI068636-14S2, UM1 AI068634, UM1
236 AI068636 and UM1 AI106701. The viral culture work was performed in the Ragon Institute
237 BSL3 core, which is supported in part by the NIH-funded Harvard University Center for AIDS
238 Research (P30 AI060354). The content is solely the responsibility of the authors and does not
239 necessarily represent the official views of the National Institutes of Health. The viral culture work
240 was performed in the Ragon Institute BSL3 core, which is supported in part by the NIH-funded
241 Harvard University Center for AIDS Research (P30 AI060354).

242

243 **Trial Registration** ClinicalTrials.gov Identifier: NCT04518410

244

245 **Acknowledgements**

246 The authors would like to thank the participants, site staff, site investigators, and the entire
247 ACTIV-2/A5401 study team. The authors would additionally like to thank the Ragon BSL3 core
248 staff.

249 **References**

- 250 1 Dougan, M. *et al.* Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. *N Engl J*
251 *Med* **385**, 1382-1392, doi:10.1056/NEJMoa2102685 (2021).
- 252 2 Weinreich, D. M. *et al.* REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with
253 Covid-19. *N Engl J Med* **384**, 238-251, doi:10.1056/NEJMoa2035002 (2021).
- 254 3 Chen, P. *et al.* SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-
255 19. *N Engl J Med* **384**, 229-237, doi:10.1056/NEJMoa2029849 (2021).
- 256 4 Chew, K. W. *et al.* Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but
257 not symptom duration in non-hospitalized adults with COVID-19. *medRxiv*,
258 2021.2012.2017.21268009, doi:10.1101/2021.12.17.21268009 (2021).
- 259 5 Choudhary, M. C. *et al.* Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody
260 Therapy. *medRxiv*, doi:10.1101/2021.09.03.21263105 (2021).
- 261 6 Planas, D. *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to antibody
262 neutralization. *Nature* **596**, 276-280, doi:10.1038/s41586-021-03777-9 (2021).

- 263 7 Wang, P. *et al.* Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature*
264 **593**, 130-135, doi:10.1038/s41586-021-03398-2 (2021).
- 265 8 Fischer, W. *et al.* Molnupiravir, an Oral Antiviral Treatment for COVID-19. *medRxiv*,
266 doi:10.1101/2021.06.17.21258639 (2021).
- 267 9 North, C. M. *et al.* Determining the Incidence of Asymptomatic SARS-CoV-2 among Early
268 Recipients of COVID-19 Vaccines: A Prospective Cohort Study of Healthcare Workers
269 before, during and after Vaccination [DISCOVER-COVID-19]. *Clin Infect Dis*,
270 doi:10.1093/cid/ciab643 (2021).
- 271 10 Siedner, M. J. *et al.* Duration of viral shedding and culture positivity with post-
272 vaccination SARS-CoV-2 delta variant infections. *JCI Insight*,
273 doi:10.1172/jci.insight.155483 (2021).
- 274 11 Yonker, L. M. *et al.* Virologic features of SARS-CoV-2 infection in children. *J Infect Dis*,
275 doi:10.1093/infdis/jiab509 (2021).
- 276 12 Wolfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature*
277 **581**, 465-469, doi:10.1038/s41586-020-2196-x (2020).
278




Figure 1




Figure 2

	Placebo arm n=39	Bamlanivimab arm n=30
Age - median (range)	50 (20-71)	50.5 (25-73)
Race – White n (%)	33 (85%)	29 (97%)
Ethnicity – Hispanic or Latino n (%)	10 (26%)	3 (10%)
Gender – Female n (%)	24 (62%)	15 (50%)
Comorbidities – At least one n (%)	12 (31%)	15 (50%)
Days of symptoms before enrollment - median (range)	4 (1-10)	5 (3-8)
Seropositive at baseline (%) ¹	0 (0%)	1 (3%)

¹4 placebo and 2 intervention arm participants had unknown serostatus at baseline

Table 1. Characteristics of participants in this substudy.